It was found that the expression of p-p38 MAPK and p-Stat3 is declined in HCC cells with myricetin treatment (Figure 5A), and cell cycle proteins Bcl-2, CyclinB1, and CyclinD1 are also significantly reduced (Figure 5A). This evidence concerns the gene BCL2 and hepatocellular carcinoma.